A New Branch on the COVID Family Tree
PJ.2.1 is a descendant of the JN.1 lineage, which was a dominant part of the Omicron family. Scientists have termed it a 'saltation variant' because it appeared with a large number of genetic changes at once, rather than evolving slowly. These mutations,
particularly on the spike protein which the virus uses to enter our cells, are what prompted researchers to take a closer look. It was first identified from a sample taken in Ontario, Canada, on May 2, 2026, and has since been detected in the United States, several European countries, Singapore, and Australia. While the World Health Organization is monitoring the variant, it has not yet been classified as a variant of interest or concern.
How Does It Spread?
One of the key questions for any new variant is whether it spreads more easily. Early data from Canada suggests PJ.2.1 is spreading relatively quickly. In Ontario, it accounted for over 25% of sequenced cases in a four-week period leading up to mid-October 2026, up from about 17% in the previous period. Laboratory studies published in the 'Journal of Infection' found that PJ.2.1's spike protein binds more effectively to the ACE2 receptor on human cells. In simple terms, it may have a better 'key' to unlock our cells, which could contribute to its growth. However, it is important to remember that lab findings do not always translate directly to real-world transmissibility between people.
What Are the Symptoms?
So far, researchers have not identified any unique symptoms that set PJ.2.1 apart from other COVID-19 variants. The World Health Organization has noted that the symptoms can be very similar to the common cold and flu, making it impossible to diagnose based on symptoms alone. The most commonly reported signs of infection include fever, cough, sore throat, a runny or blocked nose, headaches, muscle aches, and fatigue. Some reports have mentioned severe sore throat and prolonged fatigue after recovery, but this has not been broadly confirmed. Diagnostic testing remains the only reliable way to know if you have COVID-19.
Is It More Severe?
The most pressing concern with any new variant is whether it causes more severe illness. At present, there is no clinical evidence to suggest that PJ.2.1 is more dangerous than other circulating variants. Scientists and doctors are careful to distinguish between a variant that spreads faster and one that makes people sicker—the two are not necessarily linked. While surveillance is ongoing, there is currently no data showing an increase in hospitalisations or deaths associated with PJ.2.1. As with previous variants, older adults, people with weakened immune systems, and those with underlying health conditions remain at a higher risk for severe complications from any COVID-19 infection.
Do Vaccines Still Work?
Encouragingly, early lab studies suggest that PJ.2.1 does not show a major ability to evade antibodies from current vaccines. One German study found that neutralisation from an updated vaccine was only slightly reduced for PJ.2.1, a much smaller drop compared to some other variants. This suggests that while the variant has changed, our existing immunity from vaccination and prior infection should still provide a good degree of protection against severe disease. Public health officials continue to state that vaccination is a critical tool for reducing the risk of hospitalisation and death from COVID-19.
What Is the Situation in India?
As of mid-November 2026, there has been no public confirmation of widespread transmission of PJ.2.1 in India. Health experts are calling for strengthened genomic surveillance to monitor for its potential arrival and spread. Indian medical professionals have advised the public to remain informed but not to panic, emphasizing that the emergence of new variants is expected. The advice for the public remains consistent: practice good hand hygiene, wear a mask in crowded or poorly ventilated areas, and stay home and test if you develop symptoms. Particular caution is advised for elderly and high-risk individuals.
